Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
- Status
- COMPLETED
- Phase
- N/A
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- Status
- TERMINATED
- Phase
- PHASE2
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE4
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
- Status
- COMPLETED
- Phase
- PHASE2
Breast Cancer Treatment Based on Organ-like Culture
- Status
- UNKNOWN
- Phase
- N/A
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
- Status
- COMPLETED
- Phase
- PHASE1
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2